HUP0401863A2 - Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárások - Google Patents
Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárásokInfo
- Publication number
- HUP0401863A2 HUP0401863A2 HU0401863A HUP0401863A HUP0401863A2 HU P0401863 A2 HUP0401863 A2 HU P0401863A2 HU 0401863 A HU0401863 A HU 0401863A HU P0401863 A HUP0401863 A HU P0401863A HU P0401863 A2 HUP0401863 A2 HU P0401863A2
- Authority
- HU
- Hungary
- Prior art keywords
- copolymers
- mbp
- membered
- hla
- plp
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 3
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000001712 encephalitogenic effect Effects 0.000 abstract 2
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 abstract 2
- 108010072051 Glatiramer Acetate Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 108010010974 Proteolipids Proteins 0.000 abstract 1
- 102000016202 Proteolipids Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940038717 copaxone Drugs 0.000 abstract 1
- 238000011577 humanized mouse model Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
Abstract
A találmány tárgyát 14, 35 és 50 tagú, 3 és 4 aminosavból álló randomaminosav-kopolimerek képezik. Az 50-tagú FEAK hatásos inhibitora azMBP 85-99 vagy proteolipid protein (PLP) 40-60-ra specifikus HLA-DR-2-korlátozott T-sejt-klónoknak. Ezek a kopolimerek hatásosanszuppresszálták az érzékeny SJL/J (H-2s) egértörzsekben a teljesgerincvelő homogenizátummal (WSCH) vagy a PLP 139-151enkefalitogenikus epitóppal indukált EAE-t. Az 50 tagú YFAK - amelyneka mólaránya körülbelül Y 0,8:F 0,2 - hatékonyabban gátolta abiotinilált MBP 85-99 epitóp kötődését a HLA-DR-2 molekulákhoz, mint ajelöletlen MBP 85-99 vagy a Copaxone<<. Az YFAK és FAK kopolimerekhatékonyan szuppresszálták az SJL/J (H-2s) egerekben a PLP 139-151enkefalitogenikus epitóppal indukált EAE-t. Az YFK, VYAK és atriptofánt tartalmazó VWAK kopolimerek hatásosak voltak az MBP 85-99peptiddel indukált EAE súlyosságának és a tünetek időtartamának azenyhítésére olyan humanizált egérmodellben, amely egyaránt expresszáltszklerózis multiplexszel (MS) kapcsolatos HLA-DR-2 géneket és egy MS-páciensből származó T-sejt-receptort. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32670501P | 2001-10-03 | 2001-10-03 | |
PCT/US2002/031399 WO2003029276A2 (en) | 2001-10-03 | 2002-10-03 | Copolymers for suppression of autoimmune diseases, and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401863A2 true HUP0401863A2 (hu) | 2004-12-28 |
HUP0401863A3 HUP0401863A3 (en) | 2012-09-28 |
Family
ID=23273317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401863A HUP0401863A3 (en) | 2001-10-03 | 2002-10-03 | Amino acid-copolymers for suppression of autoimmune diseases, and methods of use |
Country Status (12)
Country | Link |
---|---|
US (3) | US7381790B2 (hu) |
EP (2) | EP2123669A1 (hu) |
JP (3) | JP5010798B2 (hu) |
AU (1) | AU2002362445B2 (hu) |
CA (1) | CA2462459C (hu) |
DE (1) | DE02800437T1 (hu) |
HU (1) | HUP0401863A3 (hu) |
IL (2) | IL161121A0 (hu) |
NO (2) | NO20041345L (hu) |
NZ (1) | NZ532199A (hu) |
WO (1) | WO2003029276A2 (hu) |
ZA (1) | ZA200402601B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005249A2 (en) * | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
US6930168B2 (en) * | 2001-01-24 | 2005-08-16 | The President And Fellows Of Harvard College | Synthetic peptides for demyelinating conditions |
CA2558655A1 (en) * | 2004-03-01 | 2005-09-15 | Kai W. Wucherpfennig | Methods and compositions for treatment of autoimmune diseases |
US20090275496A1 (en) * | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
WO2005120542A2 (en) * | 2004-05-07 | 2005-12-22 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
EP2586460A1 (en) | 2007-10-16 | 2013-05-01 | Peptimmune, Inc. | Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes |
WO2009075854A2 (en) * | 2007-12-10 | 2009-06-18 | Peptimmune Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
JP5916622B2 (ja) | 2010-01-04 | 2016-05-11 | マピ ファーマ リミテッド | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
ES2707500T3 (es) | 2015-11-23 | 2019-04-03 | Chemi Spa | Análisis mediante RP-HPLC de mezclas de polipéptidos complejos |
WO2018006092A1 (en) * | 2016-07-01 | 2018-01-04 | Declion Holdings Llc | Amino acid copolymer compositions and uses thereof |
MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
WO2022103673A2 (en) * | 2020-11-10 | 2022-05-19 | Fridkis Hareli Masha | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3052655A (en) * | 1958-08-01 | 1962-09-04 | Sidney W Fox | Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid |
IT1164225B (it) | 1983-05-13 | 1987-04-08 | Anic Spa | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US4996292A (en) * | 1989-06-30 | 1991-02-26 | Fox Sidney W | Self-sealing artificial skin comprising copoly-alpha-amino acid |
AU8305491A (en) * | 1990-08-01 | 1992-03-02 | Cytel Corporation | Novel immunosuppressant peptides |
US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
US5514539A (en) * | 1993-06-29 | 1996-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
DE4423131A1 (de) | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
AU730477B2 (en) | 1996-08-05 | 2001-03-08 | President And Fellows Of Harvard College | MHC binding peptide oligomers and methods of use |
US6420518B1 (en) * | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
EP1066295A2 (en) | 1998-03-23 | 2001-01-10 | President And Fellows Of Harvard College | Synthesis of compounds and libraries of compounds |
WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
EP1098902A4 (en) * | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ZA200102269B (en) * | 1998-09-25 | 2002-03-19 | Yeda Res & Dev | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use. |
US7083777B1 (en) * | 1999-04-02 | 2006-08-01 | The Brigham And Women's Hospital, Inc. | Immunomodulating polymers |
US6930168B2 (en) | 2001-01-24 | 2005-08-16 | The President And Fellows Of Harvard College | Synthetic peptides for demyelinating conditions |
CN1516598A (zh) * | 2001-06-22 | 2004-07-28 | ��ͯ����ҽԺ | 抗菌肽 |
US8017166B2 (en) | 2004-11-01 | 2011-09-13 | Steven Amory Twitty | Method of producing stackable low-fat snack chips |
-
2002
- 2002-10-03 IL IL16112102A patent/IL161121A0/xx unknown
- 2002-10-03 NZ NZ532199A patent/NZ532199A/en not_active IP Right Cessation
- 2002-10-03 CA CA002462459A patent/CA2462459C/en not_active Expired - Fee Related
- 2002-10-03 EP EP09075413A patent/EP2123669A1/en not_active Withdrawn
- 2002-10-03 AU AU2002362445A patent/AU2002362445B2/en not_active Ceased
- 2002-10-03 HU HU0401863A patent/HUP0401863A3/hu unknown
- 2002-10-03 JP JP2003532522A patent/JP5010798B2/ja not_active Expired - Fee Related
- 2002-10-03 DE DE02800437T patent/DE02800437T1/de active Pending
- 2002-10-03 WO PCT/US2002/031399 patent/WO2003029276A2/en active Application Filing
- 2002-10-03 EP EP02800437.2A patent/EP1438061B1/en not_active Expired - Lifetime
-
2003
- 2003-04-03 US US10/406,783 patent/US7381790B2/en not_active Expired - Lifetime
-
2004
- 2004-03-28 IL IL161121A patent/IL161121A/en active IP Right Grant
- 2004-03-31 NO NO20041345A patent/NO20041345L/no not_active Application Discontinuation
- 2004-04-01 ZA ZA2004/02601A patent/ZA200402601B/en unknown
- 2004-04-29 NO NO20041759A patent/NO337092B1/no not_active IP Right Cessation
-
2007
- 2007-12-26 US US12/005,239 patent/US8017125B2/en not_active Expired - Fee Related
-
2009
- 2009-04-15 JP JP2009098733A patent/JP5525749B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-12 US US13/181,079 patent/US9028835B2/en not_active Expired - Fee Related
-
2012
- 2012-04-04 JP JP2012085538A patent/JP2012162545A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20110286959A1 (en) | 2011-11-24 |
EP1438061A2 (en) | 2004-07-21 |
WO2003029276A2 (en) | 2003-04-10 |
IL161121A (en) | 2010-11-30 |
CA2462459C (en) | 2007-12-18 |
JP2012162545A (ja) | 2012-08-30 |
WO2003029276A3 (en) | 2003-11-27 |
US7381790B2 (en) | 2008-06-03 |
DE02800437T1 (de) | 2004-11-11 |
JP5525749B2 (ja) | 2014-06-18 |
ZA200402601B (en) | 2005-07-27 |
EP1438061A4 (en) | 2005-02-23 |
NZ532199A (en) | 2008-02-29 |
IL161121A0 (en) | 2004-08-31 |
HUP0401863A3 (en) | 2012-09-28 |
US20080241099A1 (en) | 2008-10-02 |
CA2462459A1 (en) | 2003-04-10 |
EP1438061B1 (en) | 2016-05-11 |
NO337092B1 (no) | 2016-01-18 |
US9028835B2 (en) | 2015-05-12 |
US20040038887A1 (en) | 2004-02-26 |
NO20041759L (no) | 2004-04-29 |
JP5010798B2 (ja) | 2012-08-29 |
JP2009185057A (ja) | 2009-08-20 |
EP2123669A1 (en) | 2009-11-25 |
NO20041345L (no) | 2004-03-31 |
AU2002362445B2 (en) | 2006-09-21 |
US8017125B2 (en) | 2011-09-13 |
JP2005511518A (ja) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401863A2 (hu) | Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárások | |
Dagosto | Implications of postcranial evidence for the origin of euprimates | |
JP2003513700A (ja) | 歯間ブラシ | |
Sichting et al. | Evolutionary anatomy of the plantar aponeurosis in primates, including humans | |
SG158733A1 (en) | Cell adhesion inhibitors | |
EA200100103A1 (ru) | Ингибиторы адгезии клеток | |
AU2003226014A8 (en) | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease | |
EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
KR20010006275A (ko) | 면역계 활성을 조절하고 염증을 억제하기 위한 세포조절 친유성 펩티드 | |
HUP0101317A2 (hu) | Módosított VIII-as faktor | |
WO2004043352A3 (en) | Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases | |
Brandfonbrener | Joint laxity and arm pain in a large clinical sample of musicians | |
US8230544B2 (en) | Multipurpose cleaning brush | |
IL206650A0 (en) | T cell receptor cdr3 peptide for treating an autoimmune disease | |
Alhendi et al. | Systemic sclerosis: update for oral health care providers | |
AU761717B2 (en) | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation | |
Muraille | Generation of individual diversity: a too neglected fundamental property of adaptive immune system | |
IL111196A0 (en) | Peptides and pharmaceutical compositions comprising them | |
WO2004043397A3 (en) | Compositions and methods for the treatment of rheumatoid arthritis | |
US20180327636A1 (en) | Disposable Handle Wrap Apparatus | |
Sofat et al. | Hand osteoarthritis—Clinical presentation, phenotypes and management | |
Reinders et al. | Survey on management of gout among Dutch rheumatologists | |
WO2004098489A3 (en) | Compositions and methods for modulation of specific epitopes of hsp60 | |
Chauhan et al. | Continuing Education Activity | |
JP2008036329A (ja) | 矯正装具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |